Robert Igwe, MD
Endocrinology, Diabetes & Metabolism · Berkley, MINPI 1871674192
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $77,621 of the $101,935 with a category attached, or 76.1%. 58 manufacturers reported payments, led by AstraZeneca at 36.9% of the total. Reporting peaked in 2019 at $35,280 and has fallen 90.4% since, to $3,401 in 2025. Among endocrinology, diabetes & metabolism clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 988 payments — averaging $103.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$38K
- Lilly USA, LLC$28K
- Johnson & Johnson$15K
- Novo Nordisk$9K
- Abbott$2K
- Dexcom, Inc.$1K
- plus $9K from 52 others
What the payments were for
- Consulting fees$3,0603%
- Speaking & faculty fees$77,62176%
- Travel & lodging$2,9563%
- Food & beverage$18,17318%
- Education$650%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$36,327
- INVOKANA$14,263
- LYUMJEV$6,500
- Tresiba$5,314
- FreeStyle Libre Pro$1,675
- Victoza$1,485
- FREESTYLE LIBRE 3$300
- TEPEZZA$249
- MINIMED 780G$190
- DEXCOM G6 TRANSMITTER$147
- TWIIST$145
- EVENITY$125
- DEXCOM G7 GSS (161)$118
- AFREZZA$112
- ZEPBOUND$109
How this compares
$101,935 in reported general payments places this provider in the 90th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
See all endocrinology, diabetes & metabolism providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 400 | $632,040 |
| MounjaroTirzepatide | 255 | $401,391 |
| JardianceEmpagliflozin | 221 | $256,119 |
| TrulicityDulaglutide | 107 | $161,333 |
| FarxigaDapagliflozin Propanediol | 114 | $135,909 |
| Novolog FlexpenInsulin Aspart | 114 | $42,167 |
| Tresiba Flextouch U-100Insulin Degludec | 59 | $39,013 |
| TradjentaLinagliptin | 26 | $38,311 |
| InvokanaCanagliflozin | 22 | $35,809 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 202 | $30,894 |
| Humalog Kwikpen U-100Insulin Lispro | 85 | $30,790 |
| JanuviaSitagliptin Phosphate | 22 | $26,580 |
| XyostedTestosterone Enanthate | 16 | $15,946 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $15,422 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $14,369 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $8,829 | $638,259414 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $27,688 | $565,548378 claims |
| Boehringer IngelheimJardiance, Tradjenta | $775 | $294,430247 claims |
| AstraZenecaFarxiga | $37,586 | $135,909114 claims |
| Johnson & JohnsonInvokana | $14,747 | $35,80922 claims |
| MerckJanuvia | $90 | $26,58022 claims |
| Antares Pharma, Inc.Xyosted | $56 | $15,94616 claims |
| AbbVieSynthroid | $151 | $12,010114 claims |
| Sanofi-aventis U.S. LLCLantus | $509 | $6,12324 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $192 | $5,188324 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
Other endocrinology, diabetes & metabolism in Berkley
- Alla SakharovaBerkley$14K
- Sander PaulBerkley$13K
- Lowell SchmeltzFarmington Hills$1.3M
- George GrunbergerBloomfield Hills$931K
- Gary EdelsonFarmington Hills$503K
- Michael BrennanSaint Clair Shores$433K
- Jamal HammoudFlint$386K
- Abdulsalam Al KassabRochester Hills$351K
- Richard AuchusAnn Arbor$250K
- Eric LangerSterling Heights$213K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.